Rheumatology

Rheumatology trials often rely on subjective assessments of disease activity and pain, leading to potential variability between evaluators and across sites.

iNGENū addresses this pain point with Standardised and Objective Assessments

We implement validated disease activity scores and patient-reported outcome measures (PROMs) such as DAS28, CDAI, or RAPID3. Comprehensive training and centralised review processes ensure consistency and accuracy in assessments across all trial sites.

Rheumatology studies frequently involve sophisticated biomarkers and imaging techniques such as ultrasound, MRI, or X-rays to assess joint damage and inflammation.

iNGENū addresses this pain point with Centralised Imaging and Biomarker Analysis

Our centralised imaging platform ensures standardised protocols and expert analysis, minimising variability. We also utilise advanced biomarker laboratories with rigorous quality control measures to ensure reliable data collection.

Finding and retaining patients in rheumatology trials can be challenging due to disease variability, strict eligibility criteria, and the chronic nature of these conditions.

iNGENū CRO addresses this pain point with Tailored Recruitment Strategies

We utilise robust patient databases, partnerships with rheumatology clinics, and collaborations with patient advocacy groups to efficiently identify and engage suitable candidates. Our patient-centric approach includes flexible scheduling, telehealth options, and continuous patient support, reducing dropout rates.

The subjective nature of symptoms in rheumatic diseases can result in significant placebo responses, complicating trial results interpretation.

iNGENū addresses this pain point with Rigorous Blinding and Statistical Techniques

We employ robust blinding methods and innovative trial designs, such as crossover or withdrawal studies, to mitigate placebo effects. Our biostatisticians use advanced statistical analyses to accurately differentiate true treatment effects from placebo responses.

Many rheumatology trials involve long-term treatments, such as biologics or immunosuppressants, which require vigilant safety monitoring due to potential adverse effects.

iNGENū addresses this pain point with Comprehensive Safety Monitoring

Our dedicated safety boards continuously monitor patient data, ensuring rapid identification and management of any adverse events. Our real-time safety reporting and proactive risk management protocols prioritise patient safety throughout the trial duration.